These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 34496081)

  • 21. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.
    Fernandez HH; Vanagunas A; Odin P; Espay AJ; Hauser RA; Standaert DG; Chatamra K; Benesh J; Pritchett Y; Hass SL; Lenz RA
    Parkinsonism Relat Disord; 2013 Mar; 19(3):339-45. PubMed ID: 23287001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion.
    Rosebraugh M; Liu W; Neenan M; Facheris MF
    J Parkinsons Dis; 2021; 11(4):1695-1702. PubMed ID: 34366380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term safety and effectiveness of levodopa-carbidopa intestinal gel infusion.
    De Fabregues O; Dot J; Abu-Suboh M; Hernández-Vara J; Ferré A; Romero O; Ibarria M; Seoane JL; Raguer N; Puiggros C; Gómez MR; Quintana M; Armengol JR; Alvarez-Sabín J
    Brain Behav; 2017 Aug; 7(8):e00758. PubMed ID: 28828219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.
    Warren Olanow C; Torti M; Kieburtz K; Leinonen M; Vacca L; Grassini P; Heller A; Heller E; Stocchi F
    Mov Disord; 2019 Mar; 34(3):425-429. PubMed ID: 30653246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review.
    Tsunemi T; Oyama G; Saiki S; Hatano T; Fukae J; Shimo Y; Hattori N
    Mov Disord; 2021 Aug; 36(8):1759-1771. PubMed ID: 33899262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
    Chang FC; Kwan V; van der Poorten D; Mahant N; Wolfe N; Ha AD; Griffith JM; Tsui D; Kim SD; Fung VS
    J Clin Neurosci; 2016 Mar; 25():41-5. PubMed ID: 26777085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson's Disease: Single Middle Eastern Center Experience.
    Bohlega S; Abou Al-Shaar H; Alkhairallah T; Al-Ajlan F; Hasan N; Alkahtani K
    Eur Neurol; 2015; 74(5-6):227-36. PubMed ID: 26618531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry.
    Antonini A; Poewe W; Chaudhuri KR; Jech R; Pickut B; Pirtošek Z; Szasz J; Valldeoriola F; Winkler C; Bergmann L; Yegin A; Onuk K; Barch D; Odin P;
    Parkinsonism Relat Disord; 2017 Dec; 45():13-20. PubMed ID: 29037498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease.
    Nyholm D; Klangemo K; Johansson A
    Eur J Neurol; 2012 Aug; 19(8):1079-85. PubMed ID: 22360705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease.
    Ferreira JJ; Poewe W; Rascol O; Stocchi F; Antonini A; Moreira J; Guimarães B; Rocha JF; Soares-da-Silva P
    Mov Disord; 2022 Nov; 37(11):2272-2283. PubMed ID: 36054562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
    Waters CH; Nausieda P; Dzyak L; Spiegel J; Rudzinska M; Silver DE; Tsurkalenko ES; Kell S; Hsu A; Khanna S; Gupta S
    CNS Drugs; 2015 Apr; 29(4):341-50. PubMed ID: 25895021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
    Pålhagen SE; Sydow O; Johansson A; Nyholm D; Holmberg B; Widner H; Dizdar N; Linder J; Hauge T; Jansson R; Bergmann L; Kjellander S; Marshall TS
    Parkinsonism Relat Disord; 2016 Aug; 29():17-23. PubMed ID: 27318707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current and novel infusion therapies for patients with Parkinson's disease.
    Antonini A; D'Onofrio V; Guerra A
    J Neural Transm (Vienna); 2023 Nov; 130(11):1349-1358. PubMed ID: 37672049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation.
    Regidor I; Santos-García D; Catalán MIJ; Puente V; Valldeoriola F; Grandas F; Mir P; Parra JC; Arbelo JM
    J Parkinsons Dis; 2019; 9(1):173-182. PubMed ID: 30562907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peripheral neuropathy in 30 duodopa patients with vitamins B supplementation.
    Rispoli V; Simioni V; Capone JG; Golfrè Andreasi N; Preda F; Sette E; Tugnoli V; Sensi M
    Acta Neurol Scand; 2017 Dec; 136(6):660-667. PubMed ID: 28608472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson's disease.
    Meloni M; Solla P; Mascia MM; Marrosu F; Cannas A
    Parkinsonism Relat Disord; 2017 Apr; 37():92-96. PubMed ID: 28063683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Adverse effects and complications of continuous intestinal infusion of levodopa-carbidopa in a cohort of patients with Parkinson's disease in a tertiary hospital].
    Campins-Romeu M; Sastre-Bataller I; Pons-Beltrán V; Baviera-Muñoz R; Losada-López M; Morata-Martínez C; Pérez-García J; Martínez-Torres I
    Rev Neurol; 2022 Mar; 74(5):143-148. PubMed ID: 35211947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study.
    Zulli C; Sica M; De Micco R; Del Prete A; Amato MR; Tessitore A; Ferraro F; Esposito P
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2413-7. PubMed ID: 27338069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.
    Fernandez HH; Standaert DG; Hauser RA; Lang AE; Fung VS; Klostermann F; Lew MF; Odin P; Steiger M; Yakupov EZ; Chouinard S; Suchowersky O; Dubow J; Hall CM; Chatamra K; Robieson WZ; Benesh JA; Espay AJ
    Mov Disord; 2015 Apr; 30(4):500-9. PubMed ID: 25545465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.